To further validate the contribution of autologous sera in personalizing the explant culture, we compared the individual effects of heterologous/allogenic sera (HS) obtained from treatment naïve patients (age, sex and cancer-type matched) with AS and recombinant EGF. The gene discussed is EGF; the disease is cancer.